BRISTOL MYERS SQUIBB
- Country
- 🇺🇸United States
- Ownership
- -
- Established
- 1989-01-01
- Employees
- 30K
- Market Cap
- $97.5B
- Website
- https://www.bms.com/
A Study to Evaluate the Drug Levels of Deucravacitinib From Tablets After Oral Administration in Healthy Participants
- First Posted Date
- 2021-07-02
- Last Posted Date
- 2022-03-11
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 61
- Registration Number
- NCT04949269
- Locations
- 🇺🇸
Quotient Sciences Miami, Miami, Florida, United States
🇺🇸PPD Development, LP, Austin, Texas, United States
A Study of BMS-986416 With and Without Nivolumab in Select Solid Tumors
- First Posted Date
- 2021-06-29
- Last Posted Date
- 2025-04-09
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 67
- Registration Number
- NCT04943900
- Locations
- 🇺🇸
Local Institution - 0006, Atlanta, Georgia, United States
🇺🇸Local Institution - 0005, Baltimore, Maryland, United States
🇺🇸Local Institution - 0002, Hackensack, New Jersey, United States
A Study to Determine the Effect of Famotidine on the Drug Levels of BMS-986256 in Healthy Participants
- First Posted Date
- 2021-06-28
- Last Posted Date
- 2022-01-21
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 22
- Registration Number
- NCT04941755
- Locations
- 🇺🇸
PPD Development, LP, Austin, Texas, United States
A Study of Participants With Squamous Cell Oesophageal Carcinoma Receiving Nivolumab as Part of an Early Access to Medicines Scheme (EAMS) Program in the United Kingdom
- Conditions
- Esophageal Squamous Cell Carcinoma
- Interventions
- Biological: Nivolumab
- First Posted Date
- 2021-06-23
- Last Posted Date
- 2022-05-25
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 87
- Registration Number
- NCT04936399
- Locations
- 🇬🇧
Local Institution - 0037, Bristol, United Kingdom
🇬🇧Local Institution, Walsall, United Kingdom
🇬🇧Local Institution - 0006, Truro, Cornwall, United Kingdom
A Study to Characterize the Drug Levels of an Oral Contraceptive With and Without BMS-986166 in Healthy Female Participants of Childbearing Potential
- First Posted Date
- 2021-06-22
- Last Posted Date
- 2022-03-18
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 25
- Registration Number
- NCT04934696
- Locations
- 🇺🇸
West Coast Clinical Trials Global, Cypress, California, United States
A Study to Assess the Safety, Tolerability and Drug Levels of BMS-986172 in Healthy and Obese Participants, Including an Assessment of the Effects of Food on BMS-986172 Absorption
- First Posted Date
- 2021-06-14
- Last Posted Date
- 2022-06-06
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 40
- Registration Number
- NCT04926051
- Locations
- 🇺🇸
ICON Plc (Legacy PRA), Lenexa, Kansas, United States
A Study to Compare the Response to Treatment With Abatacept vs Adalimumab, on Background Methotrexate, in Adults With Early, Seropositive, and Shared Epitope-positive Rheumatoid Arthritis and an Inadequate Response to Methotrexate
- Conditions
- Rheumatoid Arthritis
- Interventions
- First Posted Date
- 2021-06-02
- Last Posted Date
- 2025-02-19
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 338
- Registration Number
- NCT04909801
- Locations
- 🇮🇹
Local Institution - 0078, Perugia, Italy
🇺🇸Local Institution - 0036, Fullerton, California, United States
🇺🇸Local Institution - 0086, Los Alamitos, California, United States
A Study to Determine the Efficacy and Safety of Deucravacitinib Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Are Naïve to Biologic Disease-modifying Anti-rheumatic Drugs
- Conditions
- Psoriatic Arthritis
- Interventions
- Other: Placebo
- First Posted Date
- 2021-06-01
- Last Posted Date
- 2024-05-31
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 650
- Registration Number
- NCT04908202
- Locations
- 🇨🇳
Local Institution - 0122, Tainan, Taiwan
🇨🇳Local Institution - 0120, Taipei City, Taiwan
🇨🇳Local Institution - 0124, Taoyuan, Taiwan
A Study to Determine the Efficacy and Safety of Deucravacitinib Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Are Naïve to Biologic Disease Modifying Anti-rheumatic Drugs or Had Previously Received TNFα Inhibitor Treatment
- Conditions
- Psoriatic Arthritis
- Interventions
- First Posted Date
- 2021-06-01
- Last Posted Date
- 2025-04-13
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 729
- Registration Number
- NCT04908189
- Locations
- 🇨🇳
Local Institution - 0140, Pingxiang, Jiangxi, China
🇨🇳Local Institution - 0191, Shenyang, Liaoning, China
🇨🇳Local Institution - 0158, Baotou, Neimeng, China
A Study of BMS-986340 as Monotherapy and in Combination With Nivolumab or Docetaxel in Participants With Advanced Solid Tumors
- Conditions
- Gastric/Gastroesophageal Junction AdenocarcinomaCarcinoma, Renal CellCervical CancerNon-Small-Cell Lung CancerUrothelial CarcinomaOvarian NeoplasmsMicrosatellite Stable Colorectal CancerSquamous Cell Carcinoma of Head and NeckTriple Negative Breast NeoplasmsPancreatic Adenocarcinoma
- Interventions
- First Posted Date
- 2021-05-20
- Last Posted Date
- 2025-01-06
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 905
- Registration Number
- NCT04895709
- Locations
- 🇩🇪
Universitaetsklinikum Essen, Essen, Germany
🇺🇸Community Cancer Institute, Clovis, California, United States
🇺🇸USC/Norris Comprehensive Cancer Center, Los Angeles, California, United States